B

휴온스

243070KOSDAQ의약품 제조업

58.0 / 100

Reference Date: 2026-07-24

Financial Score22.5 / 40
News Sentiment19.6 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE significantly exceeds the industry average but Operating Profit is on a declining trend. Declined 5.2% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Hoonswell, established in 1965, is a pharmaceutical company operating in specialty drugs, beauty & wellness, and contract manufacturing (CMO). Key products include local anesthetics, functional food supplements, and medical devices, with exports to the U.S. via FDA approval. The company expanded its global presence by launching its second plant in Cheongju in 2024.

Number of Employees

1,087people

Average Salary

58.0M KRW

Score Calculation Basis

Detailed Financial Score

PER
7.22Industry Average 11.236.5Point

Lower than industry avg (good)

PBR
0.73Industry Average 0.814.0Point

In line with industry avg

ROE
11.04Industry Average 4.017.0Point

2.8x industry avg (excellent)

Debt Ratio
22.82Industry Average 12.430.5Point

1.8x industry avg (risky)

Trend 2023~20254.5 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲6.0% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼7.1% (2-year basis)

ROE Trend
2.5 / 4

Avg ROE 12.0% (declining, 3yr)

Detailed News Sentiment

33 totalPositive 28Neutral 4Negative 1Average Sentiment Score 78.2

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 25,450Won52-week high 38,20052-week low 24,700
1-month return2.0Point

1m -5.21% (slight drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral[기재정정]타인에대한채무보증결정2026-06-26
  • Neutral합병등종료보고서(합병)2026-06-26